Andre Fabrice: ESMO Tumor Agnostic Classifier and Screener
Andre Fabrice, Director of the Research Division at Gustave Roussy Cancers Center, shared on X:
“ESMO Tumor Agnostic Classifier and Screener (ETAC-S):
If preclin evidence and >20% ORR in >4 tumor types in phase I >> Tumor agnostic development.
New cancer classification being developed by ESMO : tumor-agnostic , tumor-modulated, tumor restricted.”
Authors: C.B. Westphalen, D. Martins-Branco, J.R. Beal, C. Cardone, N. Coleman, A.M. Schram, S. Halabi, S. Michiels, C. Yap, F. André, F. Bibeau, G. Curigliano, E. Garralda, S. Kummar, R. Kurzrock, S. Limaye, S. Loges, A. Marabelle, C. Marchió, J. Mateo, J. Rodon, T. Spanic, G. Pentheroudakis, V. Subbiah
Fabrice André is a prominent medical oncologist specializing in breast cancer. He holds the position of Director of the Research Division at Gustave Roussy Cancer Center and Professor of Medicine at the University Paris Saclay. Professor André also chairs the biomarker group at UNICANCER (the French cooperative group). He is the President-Elect of the European Society for Medical Oncology (ESMO).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023